American Board of Internal Medicine home page

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Medical Oncology Board Exam Committee

Robert G. Maki, MD, Chair

Dr. Maki, who is board certified in Internal Medicine and Medical Oncology, is a Professor in the Departments of Medicine and Orthopaedics, and also Section Chief in Pediatric Hematology-Oncology in the Department of Pediatrics at the Mount Sinai Medical Center in New York, New York. His efforts at Mount Sinai are directed toward an increasingly integrative effort sarcoma biology and treatment of sarcomas. His group conducts clinical trials in adults with sarcomas, and they also conduct translational studies in sarcoma biology to identify the next possible targets for new drugs to treat sarcomas. He is also the Director of Translational Oncology at the Sarcoma Alliance for Research through Collaboration.

Dr. Maki has over 25 years of experience in the biology and clinical management of sarcomas of soft tissue and bone such as gastrointestinal stromal tumors, angiosarcoma and desmoid tumors in adults and adolescents. He continues to have diverse interest in angiogenesis, epigenetics, clinical trial design and new drug development for this diverse group of malignancies. He has mentored more than 25 fellows and medical and doctoral students and continues to develop collaborative clinical and translational studies on a national and international basis.

Dr. Maki currently serves as Chair of the American Board of Internal Medicine Medical Oncology Board Exam Committee, and as a member of the Medical Oncology Board.

After receiving his medical and doctoral degrees at Cornell Medical College in New York City, he was a resident at Brigham and Women's Hospital in Boston. He then completed a medical oncology fellowship at Dana-Farber Cancer Institute, and was on staff at Dana-Farber before starting at Memorial Sloan-Kettering Cancer Institute in 1999. In 2011, he moved to the Mount Sinai Medical Center to develop the effort in adult sarcoma therapy and research.

As of January 2017, Dr. Maki reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Icahn School of Medicine at Mount Sinai Medical Center, from the following companies:

  • Eli Lilly and Company, providing funding for a trial of olaratumab in combination with three different regimens of cytotoxic chemotherapy for sarcomas.
  • Immune Design, providing funding for a trial of NY-ESO-1 vaccine strategy with concurrent PD-L1 costimulator.

Attendance at investigators' meetings, with compensation as listed, from the following company:

  • Eli Lilly and Company, for clinical trials involving olaratumab, receiving reimbursement for travel expenses and honoraria.
  • Immune Design, for trials in sarcoma, receiving reimbursement for travel expenses.
  • TRACON Pharmaceuticals, related to a trial of an investigational antivascular agent in the treatment of sarcomas, receiving reimbursement for travel expenses.

Service on a data safety monitoring board for the following companies, with compensation for travel expenses and honoraria:

  • AADi, for a nab-rapamycin Phase II study, receiving honoraria.
  • Karyopharm, for a Phase III liposarcoma study of selinexor, receiving reimbursement for travel expenses and honoraria.

Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:

  • Gem Pharmaceuticals, advising on novel anthracyclines in sarcoma studies, receiving honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation for travel expenses and/or honoraria:

  • Presage Biosciences, consulting regarding in vivo testing with small volume tissue samples as a multi-prong PDX model, receiving honoraria.

Work as an author or editor for the following company, with compensation as listed:

  • UpToDate, receiving compensation as an author and editor.

Dr. Maki serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Joint Committee on Cancer, Committee co-Chair for Sarcoma Staging System V8, reworking sarcoma staging criteria for new edition of staging system, receiving reimbursement for travel expenses and honoraria.
  • American Society of Clinical Oncology, serving as faculty at meetings and working on the cancer.net website, receiving reimbursement for travel expenses and honoraria.
  • Sarcoma Alliance for Research through Collaboration, Translational Research Committee Chair, receiving reimbursement for travel expenses and honoraria, paid to Icahn School of Medicine at Mount Sinai Medical Center.

Deborah K. Armstrong, MD

Dr. Armstrong is Professor of Oncology and of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. She is board certified in Internal Medicine and Medical Oncology and is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee.

Previously, Dr. Armstrong chaired the Oncology Drugs Advisory Committee for the US Food & Drug Administration. She was a Principal Investigator for the Gynecologic Oncology Group (now NRG Oncology), serving on Ovarian Cancer, Medical Oncology and Phase I committees. She has participated as a scientific reviewer for National Cancer Institute (NCI), Department of Defense, National Comprehensive Cancer Network and for the Stand Up to Cancer Ovarian Cancer Dream Team award, among others.

Dr. Armstrong is a member of the Board of Directors of the Society of Gynecologic Oncology. She co-chairs the Ovarian Cancer Task Force for the NCI. She is a representative of Johns Hopkins to the National Cooperative Cancer Network serving as co-chair of the ovarian cancer panel. She directs the gynecologic oncology clinical trials program at the Johns Hopkins Kimmel Cancer Center and the breast and ovarian cancer genetic counseling service that identifies patients at risk for cancer and recommends strategies for cancer screening and prevention.

Dr. Armstrong was awarded a Komen Foundation Fellowship, a Young Investigator Award from American Society of Clinical Oncology, a Career Development Award from the American Cancer Society, the Ladies Home Journal Breakthrough Achievement Award, the Rosalind Franklin Award for Excellence in Ovarian Cancer Research and the Johns Hopkins Department of Medicine Osler Housestaff Teaching Award.

Dr. Armstrong received a bachelor's degree in bacteriology from the University of California at Berkeley then attended the George Washington University School of Medicine and was elected to Alpha Omega Alpha. Dr. Armstrong trained in internal medicine at the University of Pittsburgh and served as Chief Medical Resident before completing medical oncology fellowship at the Johns Hopkins Oncology Center.

As of January 2017, Dr. Armstrong reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Johns Hopkins University, from the following companies:

  • AstraZeneca, for two ovarian cancer trials.
  • Clovis Oncology, for two ovarian cancer trials.

Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:

  • Eviti, to provide guidance for evidence-based oncology care.

Work as an author or editor for the following company, with compensation as listed below:

  • UpToDate, receiving compensation as an editor for ovarian cancer topics.

Dr. Armstrong serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Clinical Oncology, 2017 Program Committee Member, receiving compensation for travel.
  • Society of Gynecologic Oncology, Board of Directors and Co-Chair of Program Committee, receiving compensation for travel.

Wells A. Messersmith, MD

Dr. Messersmith, a board certified medical oncologist, joined the University of Colorado Cancer Center faculty in 2007 as the Director of Gastrointestinal Medical Oncology, and was appointed co-Leader of the Developmental Therapeutics Program in 2010 and Head of the Division of Medical Oncology in 2014. He was on the Johns Hopkins University faculty from 2004 to 2007 as Assistant Professor in the Gastrointestinal Oncology and Drug Development programs. Dr. Messersmith is a fellow of the American College of Physicians, and serves on the American Board of Internal Medicine Medical Oncology Board Exam Committee.

Dr. Messersmith is focused on clinical and translational cancer research and is the director of the Gastrointestinal Medical Oncology Program at the University of Colorado. This comprehensive program includes multidisciplinary gastrointestinal cancer clinics, tumor boards and research endeavors. Dr. Messersmith has held NIH R01, R21 and K23 grants and has been the Principal Investigator on approximately 50 national and local therapeutic trials, and he has published over 100 manuscripts and reviews. His laboratory has extensive experience in generating direct patient xenograft models, with a focus on Src, Notch, WNT and other anti-cancer therapies, as well as predictive biomarkers and novel combinations. Dr. Messersmith has received the National Cancer Institute (NCI)/American Society of Clinical Oncology (ASCO) Team Leadership Award and completed the ASCO Leadership Development Program. He serves on numerous national committees, including the NCI Colon Cancer Task Force, and is Director of the Academic GI Cancer Consortium.

Dr. Messersmith holds a bachelor's degree from Williams College in Williamstown, Massachusetts and a medical degree from Harvard Medical School. He trained in internal medicine at Massachusetts General Hospital/Harvard Medical School and did his medical oncology/drug development fellowship at Johns Hopkins, where he was awarded an ASCO Young Investigator Award and Passano Clinician-Scientist Award.

As of January 2017, Dr. Messersmith reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the University of Colorado, from the following companies:

  • Genentech, providing funding for several Phase I and Phase II clinical trials.
  • Immunomedics, providing funding for several Phase I clinical trials.
  • Incyte, providing funding for several Phase I clinical trials.
  • Pfizer, providing funding for several Phase I and Phase II clinical trials.
  • OncoMed Pharmaceuticals, providing funding for several Phase I clinical trials.

Service on research-related expert panel or advisory board for the following company, with compensation as listed:

  • National Comprehensive Cancer Network, for a colon/anal panel and for an investigator steering committee, without compensation.

Pamela N. Munster, MD

Dr. Munster, who is board certified in Internal Medicine and Medical Oncology, is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Developmental Therapeutics. She is the co-Leader of the BRCA Center.

She served at Memorial Sloan Kettering Cancer Center as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute, Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and co-Chair of the Phase I Program at Moffitt for six years prior to joining the University of California, San Francisco.

Her basic laboratory research interests are in the area of developing novel targeted therapy for the treatment of treatment resistant cancer and their integration into current treatment strategies. Dr. Munster's research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing HDAC inhibitors reverse hormone therapy resistance in breast cancer and to reengage the immune defense. Dr. Munster's clinical research interests are in the area of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in the germline cancer mutations.

Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research. She serves as a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee.

Dr. Munster received her medical degree from the University of Bern, Switzerland; completed her residency in internal medicine at Indiana University Medical Center then moved to Memorial Sloan Kettering Cancer Center, New York, for her oncology and hematology fellowship.

As of January 2017, Dr. Munster reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the University of California, San Francisco, from the following companies:

  • Amgen
  • AstraZeneca
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb
  • Calithera Biosciences
  • Celgene
  • Cleave Biosciences
  • Clovis Oncology
  • Corcept Therapeutics
  • Genentech
  • GlaxoSmithKline
  • Merck & Co.
  • Nektar Therapeutics
  • Novartis
  • OncoMed Pharmaceuticals
  • Roche
  • Sanofi Pasteur

Work funded by educational grants from industry, paid to University of California-San Francisco, from the following companies:

  • Dr. Munster receives fellow lecture support from multiple, unknown companies.

Olatoyosi M. Odenike, MD

Dr. Odenike, a board certified medical oncologist, is an Associate Professor of Medicine at the University of Chicago. Dr. Odenike's clinical research and medical practice is focused on myeloid malignancies, including acute and chronic leukemias, myelodysplastic syndromes and chronic myeloproliferative neoplasms. She has a particular interest in new drug development in these diseases.

Prior to joining the faculty at the University of Chicago, Dr. Odenike worked as an Attending Physician at Roseland Community hospital, a medically underserved community on the South Side of Chicago.

Dr. Odenike currently serves as a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She is co-Director of the University of Chicago Phase II Consortium, and is a member of the Alliance Leukemia Core Committee. Additionally, she has served on various professional committees including American Society of Clinical Oncology (ASCO) Scientific Program Committee for which she also served as a Track Leader, ASCO Cancer Communications Committee and the Best of ASCO Program Committee, and she has served as Chair of Educational Programs for both ASCO and the American Society of Hematology (ASH). She is also a member of the ASH Consult a Colleague Program. She has served in various editorial capacities and review committees including the Conquer Cancer Foundation of ASCO grant review committee, ASCO International Innovation Grant review subcommittee and currently serves as a member of the Aplastic Anemia/MDS International Foundation Medical Advisory Board. In addition, Dr. Odenike serves on the Molecular and Cellular Hematology National Institutes of Health Study Section. She is the recipient of an ASCO Career Development Award and was listed in Best Doctors in America as well as Castle Connolly's Top Doctors.

Dr. Odenike received her pre-medical training at the University of Ife, Nigeria, and her medical degree from the University of Ibadan, Nigeria. She completed her residency training in internal medicine and pediatrics at the University

As of January 2017, Dr. Odenike reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following companies:

  • Astex Pharmaceuticals, receiving funding for a Phase I/II study on patients with myelodysplastic syndromes.
  • Gilead Sciences, receiving funding for a Phase III study on patients with bone marrow disorders.
  • MEI Pharma, receiving funding for a Phase II study on patients with newly diagnosed acute myeloid leukemia.
  • NS Pharma, receiving funding for a Phase I/II trial of patients with bone marrow disorders.

Dipti Patel-Donnelly, MD

Dr. Patel-Donnelly, a board certified internist, medical oncologist and hematologist, is a managing partner at Virginia Cancer Specialists, which is a large multi-disciplinary private practice in Northern Virginia. She has been the co-Director of the Fairfax Stem Cell Transplant Program since 2009. Focusing on a special interest in hematologic malignancies, brain tumors and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and currently serves as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and holds a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University.

Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. She is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She is also a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology and the Medical Society of Virginia. Dr. Patel-Donnelly has received multiple awards and honors that include the Leukemia and Lymphoma Society's “Relentless for a Cure” award, Harvard Partners in Excellence Award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, NASE Achievement Scholarship and Distinguished Honors and Independent Research in Biochemistry.

Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian Magazine. Additionally, she has been listed as a Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor. She is a published author and has spoken both at local educational events and in news interviews.

Dr. Patel-Donnelly completed her fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her medical degree and completed her internal medicine internship and residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York.

As of January 2017, Dr. Patel-Donnelly reported the following external relationships:

Funding for clinical trial expenses, paid to Virginia Cancer Specialists, from the following companies:

  • Dr. Patel-Donnelly receives funding from ADC Therapeutics, Ariad Pharmaceuticals, Astellas, AstraZeneca, Boston Biomedical, Clovis, EMD Serono, Gilead Sciences, Incyte, MedImmune, Novartis, OncoMed, Merck & Co., and Roche, to support trials on solid tumors and hematologic malignancies.

Suresh S. Ramalingam, MD

Dr. Ramalingam is Professor of Hematology and Medical Oncology and the Assistant Dean for Cancer Research at the Emory University School of Medicine in Atlanta, Georgia. He is also the Roberto C. Goizueta Chair for Cancer Research and the Deputy Director of the Winship Cancer Institute of Emory University. He is board certified in both Internal Medicine and Medical Oncology.

Before joining Emory in 2007, Dr Ramalingam served as an Assistant Professor of Medicine at the University of Pittsburgh.

He is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. He serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He also serves on the editorial boards of leading cancer journals. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award, and the NCI Clinical Investigators Team Leadership Award (2010-12).

Dr. Ramalingam's research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. He has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. He has published more than 200 original manuscripts, review articles, editorials and book chapters.

Dr. Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, Michigan, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, Pennyslvania.

As of July 2017, Dr. Ramalingam reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Emory University, from the following companies:

  • Amgen, for a Phase 1 study of an anti-c-fms monoclonal antibody.
  • AstraZeneca, for a study of an EGFR inhibitor in non-small cell lung cancer.
  • Bristol-Myers Squibb, for a Phase 2 clinical trial of immunotherapy in advanced non-small cell lung cancer.
  • Pfizer, for a Phase 1 study of a novel immunotherapy combination in non-small cell lung cancer.

Service on a research-related expert panel or advisory board, receiving reimbursement for travel expenses and honoraria from the following company:

  • AstraZeneca, for a scientific advisory board to provide input on the development of EGFR inhibitors in lung cancer.

Industry-supported continuing medical education supported by the following, with reimbursement for travel expenses and honoraria:

  • PRIME, continuing medical education symposium speaker.

Work as an author or editor for following companies, with compensation as listed:

  • American Cancer Society, receiving compensation as an editor for chest disease topics for Cancer.
  • UpToDate, receiving compensation as an author.

Dr. Ramalingam serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Clinical Oncology, Chair of Professional Development Committee, receiving reimbursement for travel expenses.
  • International Association for Study of Lung Cancer (IASLC), Past Chair of Education Committee, without compensation.

David Vaughn, MD

Dr. Vaughn, board certified in Internal Medicine and Medical Oncology, is the Genitourinary Medical Oncology Professor at the Abramson Cancer Center of the University of Pennsylvania. He is also Associate Chief for Clinical Affairs in the Hematology/Oncology Division.

He is a medical oncologist with expertise in the management of patients with bladder, prostate and testicular cancers. Dr. Vaughn's clinical research is focused on development of new treatments for patient with genitourinary cancer as well as the late effects of treatment in long term survivors of testicular cancer. He is the former Chair of the American Board of Internal Medicine Medical Oncology Self-Assessment Committee and now serves as a member of the ABIM Medical Oncology Board Exam Committee.

Dr. Vaughn received his medical degree from Harvard Medical School (1987), completed his internship (1988) and residency training (1990) at New York Hospital Cornell Medical Center and fellowship training at the Hospital of the University of Pennsylvania (1993).

As of January 2017, Dr. Vaughn reported the following external relationships:

Work as an author or editor for following company, with compensation as listed:

  • UpToDate, receiving compensation for authorship on section on testicular cancer survivors.

Lori J. Wirth, MD

Dr. Wirth is the Medical Director of the Head and Neck Oncology Program at Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. Before joining Mass General in 2008, Dr. Wirth was on staff at the Dana-Farber Cancer Institute. She is board certified in Medical Oncology.

Dr. Wirth is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She currently serves as the Chairperson of the International Thyroid Oncology Program and sits on the National Comprehensive Cancer Network's Thyroid Carcinoma Guidelines Panel. She is also a member of the Dana-Farber/Harvard Cancer Center Scientific Review Committee. She has previously served on the Dana-Farber/Harvard Cancer Center Institutional Review Board and the National Cancer Institute's Head and Neck Cancer Steering Committee Recurrent/Metastatic Disease Task Force, and has recently served on the American Joint Committee on Cancer's Endocrine Expert Panel.

Dr. Wirth received her bachelor's degree from Brown University and medical degree from Columbia University's College of Physicians and Surgeons. She completed her internal medicine residency at New York Presbyterian Medical Center-Columbia Presbyterian, and completed a three-year fellowship in the Dana-Farber/Partners CancerCare Hematology/Oncology Program.

As of July 2017, Dr. Wirth reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Massachusetts General Hospital, from the following companies:

  • AstraZeneca, for a study of selumetinib in thyroid cancer and for a study of 5-azacytadine, durvalumab, tremilimumab for recurrent squamous cell carcinoma of the head and neck, receiving funding for clinical trial expenses and staff.
  • Bayer, for an observational study of thyroid cancer, receiving funding for clinical research staff.
  • Eisai, for a study of lenvatinib in thyroid cancer and in a combination Phase I trial, receiving funding for clinical trial expenses and staff.
  • Merck, for a Phase Ib trial with pembrolizumab, receiving funding for clinical trial expenses and staff.

Service on a research-related expert panel or advisory board, receiving honoraria, from the following company:

  • Blueprint Medicine, for service on an advisory board for a RET inhibitor.
  • Loxo Oncology, for service on an advisory board for a RET inhibitor.